Myelodysplastic Syndrome (MDS) & Chronic Myelomonocytic Leukemia (CMML)

**HIGHER RISK MDS**
- Naive to Hypomethylating Agents
  - **HEMMDS0039**
    - Phase III
    - Maptorlimab in Combo w/ Azacitidine vs Azacitidine + Placebo in Treatment-Naive High-Risk MDS
    - PI: Greenberg
    - Sponsor: Gilead Sciences, Inc.
    - Priority 1
  - **HEMMDS0043**
    - Cellular and Humoral Modulation of Hemopoiesis
    - PI: Greenberg
    - Sponsor: Stanford University

**LOWER RISK MDS**
- Failure to respond to Erythropoietic stimulating Agent
  - **HEM0056**
    - Phase I/II
    - Safety & Efficacy of Eenasidenib in MDS/Myelomonocytic Leukemia without IDH2 Mutation
    - PI: Zhang
    - JHT
    - Sponsor: Stanford University
    - Priority 1
  - **HEMMDS0043**
    - Cellular and Humoral Modulation of Hemopoiesis
    - PI: Greenberg
    - Sponsor: Stanford University
  - **HEMMDS0042**
    - Phase I/II
    - INCB000928 Monotherapy in Subjects w/ Anemia Due To Myelodysplastic Syndromes / Multiple Myeloma
    - PI: Shomali
    - Sponsor: Incyte Corporation
    - Priority 2

**KEY**
- Pending
- Open for Enrollment
- Link
- Optional Path
- Enrollment on Hold
- Trial Posting
- Extension Study
- Immunotherapy